Kodiak Sciences Inc. (KOD)
| Market Cap | 5.78B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -189.00M |
| Shares Out | 51.57M |
| EPS (ttm) | -3.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 190,187 |
| Open | 111.32 |
| Previous Close | 109.66 |
| Day's Range | 109.38 - 113.45 |
| 52-Week Range | 73.19 - 171.21 |
| Beta | 1.37 |
| Analysts | Buy |
| Price Target | 121.55 (+8.6%) |
| Est. Earnings Date | Nov 8, 2021 |
About KOD
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in researching, developing, and commercializing therapeutics to treat retinal diseases in the United States and international markets. Its lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy, including diabetic macular edema, as well as for macular edema due to retinal vein occlusion. The company's preclinical stage pr...
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for KOD stock is "Buy." The 12-month stock price forecast is 121.55, which is an increase of 8.56% from the latest price.
News
3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
Kodiak Sciences Inc. (KOD) Up 15.7% Since Last Earnings Report: Can It Continue?
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak Sciences Announces New Long-Term Performance Incentive Plan
PALO ALTO, Calif. , Sept. 1, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to...
Kodiak Sciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
PALO ALTO, Calif., Aug. 31, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...
Kodiak Sciences (KOD) Q2 Earnings Lag, Eye Candidate in Focus
Kodiak Sciences (KOD) reports wider-than-expected loss for the second quarter of 2021. Pipeline development remains in focus for the company.
Kodiak Sciences Announces Second Quarter 2021 Financial Results and Recent Business Highlights
PALO ALTO, Calif., Aug. 9, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...
Is This Mid-Cap Biotech Stock a Buy Now?
This mid-cap growth stock could be a long-term winner.
Kodiak Sciences Has Declined $125M Funding From Baker Bros Citing Strong Balance Sheet
In December 2019, Kodiak Sciences Inc (NASDAQ: KOD) entered into a funding agreement with Baker Bros Advisors LP, wherein Baker Bros agreed to fund up to $225 million in exchange for the right to 4.5% r...
Why Is Kodiak Sciences Inc. (KOD) Down 4% Since Last Earnings Report?
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak Sciences to Present at Upcoming Conferences
PALO ALTO, Calif., May 20, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Kodiak Sciences Inc. - KOD
NEW YORK, May 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kodiak Sciences Inc. ("Kodiak" or the "Company") (NASDAQ: KOD). Such investors are advised to cont...
Kodiak Sciences (KOD) Q1 Earnings Miss, KSI-301 in Focus
Kodiak Sciences (KOD) reports wider-than-expected loss for the first quarter of 2021. Pipeline development remains in focus for the company.
Why Kodiak Sciences Stock Is Tumbling Today
The company provided a first-quarter update with news that it's launching another late-stage clinical study of its lead candidate.
Kodiak Sciences Announces First Quarter 2021 Financial Results and Recent Business Highlights
PALO ALTO, Calif., May 10, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...
What Makes Kodiak Sciences Inc. (KOD) a New Buy Stock
Kodiak Sciences Inc. (KOD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Kodiak Sciences (KOD) Misses on Q4 Earnings, KSI-301 in Focus
Kodiak Sciences (KOD) reports wider-than-expected loss in the fourth quarter of 2020. The company is making good progress with the development of its lead pipeline candidate, KSI-301.
Kodiak Sciences Announces Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
PALO ALTO, Calif., March 1, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...
Kodiak Sciences' KSI-301 Shows Durable Benefit In Retinal Disease Settings
Kodiak Sciences Inc (NASDAQ: KOD) announced new data from one-year durability, efficacy, and safety data from the ongoing Phase 1b study evaluating KSI-301, an intravitreal anti-VEGF antibody biopolymer...
Kodiak Sciences Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1b Study of KSI-301 in Patie...
PALO ALTO, Calif., Feb. 13, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...
Kodiak Sciences Announces Upcoming Presentation of KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, a...
PALO ALTO, Calif., Feb. 2, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...
Kodiak Sciences to Present at the J.P. Morgan Healthcare Conference
PALO ALTO, Calif., Jan. 5, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...
Kodiak Sciences Announces Closing of $645.0 Million Public Offering of Common Stock and Full Exercise of Underwriters...
PALO ALTO, Calif., Nov. 20, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...
Kodiak Sciences Announces Pricing of $560.9 Million Public Offering of Common Stock
PALO ALTO, Calif., Nov. 17, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...
Kodiak Sciences Announces Proposed Offering of Common Stock
PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...